Iterative Scopes today announced a partnership to bring its AI recruitment (AIR) technology to One GI’s clinical research.
The partnership stipulates that, initially, One GI uses AIR at its Gastro One clinical research site in Memphis, Tennessee. It then plans to expand to additional research sites within the One GI network.
Cambridge, Massachusetts-based Iterative Scopes said implementing AIR aids in the recruitment of patients for clinical trials. Those trials focus on inflammatory bowel disease (IBD).
One GI, a gastroenterology management services organization (MSO), has 40 sites within its network. That spans across Tennessee, Mississippi, Kentucky, Ohio, and Indiana.
The partnership allows One GI physicians to leverage Iterative Scopes’ AI-based technology. It enables the standardization of the endoscopic scoring process for patients. This also helps helps to identify potentially eligible IBD patients to enroll in trials. Iterative Scopes said that Dr. Ziad Younes, a “global leader in gastroenterology,” is leading the collaboration.
Iterative Scopes, One GI to “deliver world-class GI care”
“Our partnership with Iterative Scopes enables the delivery of innovative technology to community-based gastroenterology practices, demonstrating One GI’s commitment to physician-centered, patient-focused healthcare,” said Robbie Allen, CEO of One GI. “Our ultimate mission is to power practices – regardless of their location – to deliver world-class GI care, and implementing AIR will allow a broader array of patients to access potentially life-changing clinical trials.”
Iterative Scopes’ AIR simplifies the process of matching patients to clinical trials, the company said. It helps gastroenterologists better understand disease severity more quickly and consistently. The technology uses computational algorithms integrated with existing colonoscopy imagery and videos to determine clinical trial eligibility. Iterative Scopes said this speeds up clinical trial timelines and opens access to potentially life-changing treatments.
“Iterative Scopes’ mission is to democratize access to high-quality care for patients struggling with IBD and other GI conditions, ultimately reducing healthcare disparities in clinical practice,” said Sahir Raoof, VP of business development at Iterative Scopes. “We are thrilled to be partnering with Dr. Younes and One GI to drive clinical adoption of artificial intelligence to help us advance clinical trial recruitment in an effort to help bring novel therapeutics to IBD patients faster.”
